Ra Medical Systems to Report Third Quarter 2021 Financial Results on November 15, 2021

Rhea-AI Summary

Ra Medical Systems (NYSE American: RMED) will announce its third quarter 2021 financial results on November 15, 2021, after market close. An investment community conference call is scheduled for 1:30 PM PT that day to discuss the financial results and provide a company update. The call will be accessible via pre-registration, and a live webcast will be available, archived for 30 days. Ra Medical produces the DABRA excimer laser system for treating vascular diseases, with FDA and CE mark clearances for various applications.

Positive

• Upcoming conference call on November 15, 2021, provides an opportunity for investors to gain insights.
• DABRA system has FDA clearance for treatment of infrainguinal lower extremity vascular disease.

Negative

• None.

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ra Medical Systems, Inc. (NYSE American: RMED) announces that it will report third quarter 2021 financial results after market close on Monday, November 15. Ra Medical management will hold an investment community conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss financial results and provide a company update.

Pre-Registration		Participants can pre-register for the conference call here:
		Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.
Live Call:		Those who choose not to pre-register can access the live conference by dialing:
		U.S.		866-777-2509
		International		412-317-5413
		Passcode		10161581
Live Webcast:		Ra Medical Website
		The webcast will be archived for 30 days.
Replay:		U.S.		877-344-7529
		Canada		855-669-9658
		International		412-317-0088
		Passcode		10161581
		The replay will be available for 48 hours

About Ra Medical Systems

Ra Medical Systems manufactures the DABRA excimer laser and catheters for the treatment of vascular diseases. DABRA has been cleared by the FDA for crossing chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease and has an intended use for ablating a channel in occlusive peripheral vascular disease. In addition, DABRA has been granted CE mark clearance for the endovascular treatment of infrainguinal arteries via atherectomy and for crossing total occlusions. DABRA breaks down plaque to its fundamental chemistry, such as proteins, lipids and other chemical compounds, eliminating blockages by essentially dissolving them without generating potentially harmful particulates. DABRA excimer lasers and catheters are manufactured in a 32,000-square-foot facility located in Carlsbad, Calif. The vertically integrated facility is ISO 13485 certified and is licensed by the State of California to manufacture sterile, single-use catheters in clean room environments.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211108005038/en/

At the Company:

Andrew Jackson

Chief Financial Officer, Ra Medical Systems

760-496-9540

ajackson@ramed.com

Investors:

LHA Investor Relations

Jody Cain

310-691-7100

jcain@lhai.com

Source: Ra Medical Systems, Inc.

FAQ

When will Ra Medical Systems report its third quarter 2021 financial results?

Ra Medical Systems will report its third quarter 2021 financial results on November 15, 2021, after market close.

What time is the conference call for Ra Medical's financial results?

The conference call for Ra Medical's financial results is scheduled for 1:30 PM Pacific Time on November 15, 2021.

How can I access the Ra Medical Systems conference call?

Participants can pre-register for the conference call to gain immediate access or dial in directly using the provided phone numbers.

What products does Ra Medical manufacture?

Ra Medical manufactures the DABRA excimer laser and catheters for the treatment of vascular diseases.

What clearances does the DABRA system have?

The DABRA system has FDA clearance and CE mark clearance for various vascular treatments.